Effect of DHEA on Patients With Poor Ovarian Responds

Last updated: July 18, 2023
Sponsor: The Affiliated Hospital of Inner Mongolia Medical University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Infertility

Treatment

placebo(medical starch)

Dehydroepiandrosterone

Clinical Study ID

NCT02432248
S00056W9
  • Ages 21-42
  • Female

Study Summary

The purpose of this study is to investigate the effect of DHEA for treatment of subfertile patients with poor ovarian reserve and post-treatment evaluation of IVF outcome.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Indicated for IVF treatment according to our standard department protocol
  • Age < 42
  • Regular menstrual cycles (21-35 days) Poor ovarian responders are defined according to the Bologna criteria fulfilling 2 out of 3of the following:
  • Advanced maternal age (≥40) or any other genetic or acquired risk factor for POR
  • Previous poor ovarian response (POR) (≤3 oocytes with a conventional stimulationprotocol using at least 150IU gonadotrophins per day)
  • Abnormal ovarian reserve test (i.e. AFC < 5-7 or AMH < 0.5-1.1ng/ml). Alternatively,two episodes of POR after maximal stimulation are sufficient to define a patient aspoor responder in the absence of advanced maternal age or abnormal ORT.

Exclusion

Exclusion Criteria:

  • Previous chemotherapy or pelvic irradiation
  • Polycystic ovarian syndrome or polycystic ovaries
  • On hormonal supplementation for any indication at the time of recruitment (e.g.estrogen, testosterone or DHEA)

Study Design

Total Participants: 350
Treatment Group(s): 2
Primary Treatment: placebo(medical starch)
Phase:
Study Start date:
February 01, 2015
Estimated Completion Date:
December 31, 2024

Study Description

The aim of this randomized controlled study is to compare the effect of DHEA and placebo on live birth rate in poor ovarian responders. Consecutive infertile women attending the subfertility clinic for IVF treatment will be approached. Those fulfilling the selection criteria would be recruited and a written consent will be obtained after detailed explanation and counseling.

Baseline assessment will be performed at early follicular phase (Day 2 or 3) at recruitment. Patient characteristics including age, body mass index (BMI), and smoking status would be recorded and blood test including follicular stimulating hormone (FSH), estradiol (E2), testosterone and anti-Müllerian hormone (AMH) would be checked. Pelvic scan will be performed to assess the total antral follicle count (AFC) and total ovarian volume.

Subjects will be randomized divided into two groups:

  1. DHEA group: Subjects will take DHEA (Vitacost) 25mg three times a day for 12 weeks prior to the start of IVF treatment.

  2. Placebo group: Subjects will take placebo three times a day for 12 weeks prior to the start of IVF treatment.

Ultrasound assessment will be repeated in follicular phase (D2 or 3) of every month or cycle followed by a IVF treatment using antagonist protocol based on our standard departmental regimen. Cycle characteristics including the dose of gonadotrophins use, duration of stimulation, number of oocytes obtained, number of fertilized embryos and good quality embryos will be recorded and follicular fluid will be saved for hormonal profiles.

Connect with a study center

  • The Affiliated Hospital of Inner Mongolia Medical University

    Inner Mongolia,
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.